Member Info for AB124

C11,
OK technically but two trials not effectively fully populated and producing the Dataset required of the parameters.
So maybe I should have said ,
"No bloody trials fully recruited producing the data required and running in the timeframe as intended"
Appreciate your pointing out my lack of precision.

WTP
If nothing has changed as you say, why do you feel the need to invest more money?
If there was a positive change in the situation that might make sense, but why add more now when you were obviously happy with the amount you had in last time we were at 14.825p?
I'm intrigued.

Because Bojo when you've seen your investment surface after for being underwater for eight/nine years and then seen it double and then see the SP beginning to threaten your base price (lets say 13p where oh so many revealed their base to be last year) I imagine some feel very jittery.
I'm not advising others to sell or buy here (that's their decision) but to suggest , "selling on delays is a mistake" certainly wasn't for anyone who sold in 2013 because a cash raiser arrived due to delays did rather well out of their decision. Scancell have history and yet the same two people are again leading the company. Certainlty one is temporary so how long to recruit his replacement?
We need DATA WITHOUT DELAYS.
How do we do that?
Not a difficult one to answer, a bit tougher to implement.
As I said earlier I live in hope for Scancell.
If it did all fall apart (for whatever reason) at least it is one investment among many. That's what allows me to try and see both sides of any argument about progress.
AIMO

C11
Yep, we have Covidity but that's what everyone expects was the reason for the SP drop... (IE we have a trial with indeterminate numbers but not yet producing data that people care about - Covid's beaten in the view of some investors).
As to Modi have we first dosed yet?
if not, to all intents and purposes, we don't have a trial running on the saviour of the science (Moditope) TEN YEARS after its discovery.
Serendipitous indeed?
That may not be a fair assessment but I'll bet its what a great many sellers ove the last couple of weeks believe.
If that is the case then maybe some useful updates from the company to the (long suffering) shareholders would be helpful unless there's really nothing to report which rather supports the last few sentences.
I think the provision of DATA is probably the most importatnt aspect for the SP, or even a facility for providing DATA (recruited and active trials).
AIMO

Crumbs,
I suspect we need DATA.
It's all very well talking about partnerships but to get real partnerships forged we need proven assets.
Sadly we've been here before. Wonderful science but no bloody trials running.
FFS we even apparently turned deals down. That's fine, BUT time marches on and some evidence of commercial progression would be helpful. Timelines have been extended once more (ref CLNs) and the LTH yet again have no clue as to what's going on.
Glad we have the same team at the top as we had in 2012.
Hang on, it's 2022 now.
How's the commercialisation going chaps?
Roll on 2032?
So now Covidity seems to be the reason for SP weakness PLEASE could we see some evidence that some DATA will soon be forthcoming.
At the moment that seems to be the holy grail for Scancell.
A bit of DATA.
AIMO

Cleanerworld,
Your 11.32 great response to Kashdog. Great to see your objectivity too!
Good to see all views considered and acknowledged.

OK

Cleanerworld
The heading to this thread is misleading.
Vulpes and RM's average is way, way below 19.5p

OK....

Cleanerworld,
It says a date of
02:45 Fri 10 May 2019
on that article.
Am I missing something or were you making some other point?

Berm
"Why Backdated?"
I was going to glibly write, "Because it's Feberuary" but I see what you mean.
Maybe Scancell decided not to tell us (if it's actually the case)!
Don'cha just love the Scancell information line?
Wonder what else they've forgotten to tell.
Maybe a part time press officer would be helpful. The shareholders could club together and put up the money to pay for the position..... Oh hang on, we've been doing that already haven't we?
AIMO

Linkedin says appointed in Jan 2022
Must be a payrise and new position backdated?
Can't see any company announcement. But seemingly not a new appt.
I'm sure Scancell will tell us ... ......eventually. ??
AIMO

Sorry Roses my post didn't take for ages.

Published
Can't post link sorry

RP
Well QUOTED sir!

Ratcliffewriter
I seem to be regularly posting in reply to some of your posts and on several occasions I've referred to the concept of "evidence" and its veracity.
I didn't remember the interview quite like that having seen it since 2013.
With regard to your 18.05 post I see you have made the case for RG's statements regarding the sale of Immunobody from his statements in the “Frankfurt” video; that the hope of the sale of Immunobody stopped when Moditope arrived?
It did not.
Did he say as you quote him,
'Multiples of the current share price'?
He did not.
Have a look at the video (link below).
Your post suggests that Moditope changed the way that Scancell viewed the sale of Immunobody (ie it prevented or changed it). In the eyes of RG in Feb 2013 he was still being talking about as a sale by late 2013 or 2014. Moditope did not come along and stop the desire (by at least one senior Board member) for the sale of Immunobody, or the company, for a long time. Seems amazing now but there was still a BOD view that Immunobody could be sold even with the serendipitous discovery being in the fold but that was actually the case.
Anyway, have a watch and a listen to the interview you quoted and see how memory can be a very dangerous thing to rely on when lecturing!

hxxp://www.youtube.com/watch?v=E-J5J7bBQDs

I like the quote from the interview,
"Our [Scancell's] future is quite short"
That was stated on 27th Feb 2013.... I'd hate to see what timescale would be required for the idea of a long, hard slog!!
AIMO

JohnnyB1
You are not going to be a very popular bunny in some quarters with your 13.34 if your conclusions are valid.
But even so June isn't far away , so maybe a bit of realism might be allowed to settle in here.
I do hope so....

RR
Agreed.
I would say Data is the key, and as soon as we get some we'll have something to get our teeth into...
Hopefully :-)
AIMO

C7
My last on this,
"if they felt the share was due a rise prior to the RNS they might have bought at 21p, what other reason could there be?"
Firstly that's not a reason, it's your idea that IIs think the same way as PIs.
They don't.
Last week when I said I didn't believe you were correct in believing that Vulpes were buying it was because they have recently been supporting the SP (very publicly). That was after watching the SP reaction to any new news which has been for a rise and shortly after an SP drop.
AFTER THE DROP is when I posted I expected Vulpes to arrive and now some on this BB are calling the larger trades to be possibly Vulpes. I wouldn't disagree with that view.
That's a REASON! People have looked at the history and seen what might be happening.
Finally you were suggesting on a 22.25P buy ON 12TH JAN that Vulpes (in your opinion ) was the buyer,
"Price: 21.50
Buy
RE: 22.25 PAID/TICK UP12 Jan 2022 11:24
I have a sneaky feeling we just might see Vulpes adding to their holding preceding the Interim Results on the 26th."

Just wanted to put everything into context.
Now hopefully we can put this to bed.
AIMO

Actually no, you've never given a reason as to why they would buy at last week's levels.
No worries, I'll stick with my idea of having a look at where we close today.